SUPPORTING INFORMATION FOR

Toward a carbohydrate-based HIV-1 vaccine: Synthesis and immunological studies of oligomannose-containing glycoconjugates

Jiahong Ni, Haijing Song, Yadong Wang, Nicholas M. Stamatos, and Lai-Xi Wang*


Institute of Human Virology, University of Maryland Biotechnology Institute, University of Maryland, Baltimore, MD 21201, USA

Running title: Carbohydrate-based HIV-1 vaccine

CONTENTS:

Figure S1. HPLC profile of the glycopeptide Man9Cluster-Pep	.S2
Figure S2. ESI-MS spectrum of the synthetic glycopeptide Man9Cluster-Pep	.S3
Figure S3. HPLC profile of the synthetic glycoconjugate Man9-Pep	.S4
Figure S4. ESI-MS spectrum of the synthetic glycopeptide Man9-Pep	S5

Figure S1. HPLC profile of the glycopeptide Man9Cluster-Pep (10)



Analytical HPLC was carried out with a Waters 626 HPLC instrument on a Waters Nova-Pak C18 column (3.9x150 mm) at 40 °C. The column was eluted with a linear gradient (0.90%) of MeCN containing 0.1% TFA within 25 min at a flow rate of 1 mL/min with UV (214 nm) detection.

Figure S2. ESI-MS spectrum of the glycopeptide Man9Cluster-Pep (10)





Figure S3. HPLC profile of the glycopeptide Man9Cluster-Pep (13)



Analytical HPLC was carried out with a Waters 626 HPLC instrument on a Waters Nova-Pak C18 column (3.9x150 mm) at 40 °C. The column was eluted with a linear gradient (0.90%) of MeCN containing 0.1% TFA within 25 min at a flow rate of 1 mL/min with UV (214 nm) detection.

Figure S4. ESI-MS spectrum of the glycopeptide Man9Cluster-Pep (13)

